Florin-Andrei Taran
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L. Return of individual genomic research results within the PRAEGNANT multicenter registry study. Breast Cancer Res Treat 2022
Nov 21, 2022Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Nov 21, 2022Breast Cancer Res Treat 2022
Huebner Hanna, Ruebner Matthias, Kurbacher Christian, Hadji Peyman, Hartkopf Andreas D, Lux Michael P, Huober Jens, Uhrig Sabrina, Taran Florin-Andrei, Overkamp Friedrich, Tesch Hans, Häberle Lothar, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Hein Alexander, Belleville Erik, Untch Michael, Janni Wolfgang, Fehm Tanja N, Kolberg Hans-Christian, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Ettl Johannes, Fasching Peter A, Michel Laura L
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"
Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". Breast 2021; 55:138-139.
Jan 5, 2021Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"
Jan 5, 2021Breast 2021; 55:138-139
Schneeweiss Andreas, Lux Michael P, Müller Volkmar, Nabieva Naiba, Overkamp Friedrich, Tesch Hans, Laakmann Elena, Taran Florin-Andrei, Seitz Julia, Thomssen Christoph, Untch Michael, Wimberger Pauline, Wuerstlein Rachel, Volz Bernhard, Wallwiener Diethelm, Wallwiener Markus, Klein Evelyn, Kurbacher Christian M, Ettl Johannes, Luftner Diana, Beckmann Matthias W, Belleville Erik, Fasching Peter A, Fehm Tanja N, Geberth Matthias, Häberle Lothar, Hadji Peyman, Hartkopf Andreas D, Hielscher Carsten, Huober Jens, Ruckhäberle Eugen, Janni Wolfgang, Kolberg Hans Christian, Brucker Sara Y
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
Huebner H, Beckmann M, Belleville E, Ruebner M, Untch M, Fasching P, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Müller V, Wallwiener M, Kurbacher C, Kuesters G, Hartkopf A, Lux M, Huober J, Volz B, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC cancer 2020; 20:1091.
Nov 11, 2020Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
Nov 11, 2020BMC cancer 2020; 20:1091
Huebner Hanna, Beckmann Matthias W, Belleville Erik, Ruebner Matthias, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Kolberg Hans-Christian, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Müller Volkmar, Wallwiener Markus, Kurbacher Christian M, Kuesters Geoffrey, Hartkopf Andreas D, Lux Michael P, Huober Jens, Volz Bernhard, Taran Florin-Andrei, Overkamp Friedrich, Tesch Hans, Häberle Lothar, Luftner Diana, Ettl Johannes
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Michel L, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Wimberger P, Huebner H, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Fehm T. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers (Basel) 2020; 12
Oct 17, 2020Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Oct 17, 2020Cancers (Basel) 2020; 12
Michel Laura L, Hielscher Carsten, Mundhenke Christoph, Kurbacher Christian, Wuerstlein Rachel, Untch Michael, Overkamp Friedrich, Huober Jens, Janni Wolfgang, Taran Florin-Andrei, Lux Michael P, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Wimberger Pauline, Huebner Hanna, Hartkopf Andreas D, Fasching Peter A, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Belleville Erik, Volz Bernhard, Fehm Tanja N
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54:88-95.
Aug 29, 2020Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Aug 29, 2020Breast 2020; 54:88-95
Schneeweiss Andreas, Lux Michael P, Müller Volkmar, Nabieva Naiba, Overkamp Friedrich, Tesch Hans, Laakmann Elena, Taran Florin-Andrei, Seitz Julia, Thomssen Christoph, Untch Michael, Wimberger Pauline, Wuerstlein Rachel, Volz Bernhard, Wallwiener Diethelm, Wallwiener Markus, Klein Evelyn, Kurbacher Christian M, Ettl Johannes, Luftner Diana, Beckmann Matthias W, Belleville Erik, Fasching Peter A, Fehm Tanja N, Geberth Matthias, Häberle Lothar, Hadji Peyman, Hartkopf Andreas D, Hielscher Carsten, Huober Jens, Ruckhäberle Eugen, Janni Wolfgang, Kolberg Hans Christian, Brucker Sara Y
Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
Kolberg H, Wallwiener M, Overkamp F, Tesch H, Ettl J, Luftner D, Müller V, Schütz F, Fasching P, Taran F, Hartkopf A, Janni W, Schneeweiss A, Fehm T, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux M, Brucker S. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Frauenheilkd 2019; 79:470-482.
May 21, 2019Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
May 21, 2019Geburtshilfe Frauenheilkd 2019; 79:470-482
Kolberg Hans-Christian, Wallwiener Markus, Overkamp Friedrich, Tesch Hans, Ettl Johannes, Luftner Diana, Müller Volkmar, Schütz Florian, Fasching Peter A, Taran Florin-Andrei, Hartkopf Andreas D, Janni Wolfgang, Schneeweiss Andreas, Fehm Tanja N, Wöckel Achim, Huober Jens, Pontones Constanza, Titzmann Adriana, Belleville Erik, Lux Michael P, Brucker Sara Y
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Lux M, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Belleville E, Beckmann M, Müller V, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Brucker S. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers (Basel) 2018; 11
Dec 21, 2018Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Dec 21, 2018Cancers (Basel) 2018; 11
Lux Michael P, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Schneeweiss Andreas, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Nabieva Naiba, Hartkopf Andreas D, Huober Jens, Volz Bernhard, Taran Florin-Andrei, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Brucker Sara Y
Update Breast Cancer 2017 - Implementation of Novel Therapies
Lux M, Wallwiener M, Müller V, Beckmann M, Belleville E, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Luftner D, Huober J, Ettl J, Janni W, Hartkopf A, Nabieva N, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Fasching P. Update Breast Cancer 2017 - Implementation of Novel Therapies. Geburtshilfe Frauenheilkd 2017; 77:1281-1290.
Dec 18, 2017Update Breast Cancer 2017 - Implementation of Novel Therapies
Dec 18, 2017Geburtshilfe Frauenheilkd 2017; 77:1281-1290
Lux Michael P, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Belleville Erik, Fehm Tanja N, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Luftner Diana, Huober Jens, Ettl Johannes, Janni Wolfgang, Hartkopf Andreas D, Nabieva Naiba, Taran Florin-Andrei, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Fasching Peter A
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
De Gregorio A, Janni W, Fasching P, Taran F, Hartkopf A, Jaeger B, Meier-Stiegen F, Pantel K, Schneeweiss A, Mueller V, Riethdorf S, Alunni-Fabbroni M, Trapp E, Rack B, De Gregorio N, Scholz C, Huober J, Friedl T, Fehm T. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO Precis Oncol 2017; 1:1-12.
Nov 1, 2017Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
Nov 1, 2017JCO Precis Oncol 2017; 1:1-12
De Gregorio Amelie, Janni Wolfgang, Fasching Peter A, Taran Florin-Andrei, Hartkopf Andreas, Jaeger Bernadette, Meier-Stiegen Franziska, Pantel Klaus, Schneeweiss Andreas, Mueller Volkmar, Riethdorf Sabine, Alunni-Fabbroni Marianna, Trapp Elisabeth, Rack Brigitte, De Gregorio Nikolaus, Scholz Christoph, Huober Jens, Friedl Thomas W P, Fehm Tanja
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Hartkopf A, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Belleville E, Beckmann M, Müller V, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Luftner D, Wallwiener M, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast 2017; 37:42-51.
Oct 26, 2017Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Oct 26, 2017Breast 2017; 37:42-51
Hartkopf Andreas D, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Fersis Nikos, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Brucker Sara Y, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Huober Jens, Volz Bernhard, Nabieva Naiba, Taran Florin-Andrei, Schwitulla Judith, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Lux Michael P, Luftner Diana, Wallwiener Markus, Schneeweiss Andreas
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program
Schramm A, Janni W, Wallwiener D, Taran F, Hartkopf A, Meier-Stiegen F, Pantel K, Schneeweiss A, Müller V, Alunni-Fabbroni M, Trapp E, Rack B, Huober J, De Gregorio N, Scholz C, Schochter F, Friedl T, Fehm T. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet 2015; 293:271-81.
Sep 9, 2015Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program
Sep 9, 2015Arch Gynecol Obstet 2015; 293:271-81
Schramm Amelie, Janni Wolfgang, Wallwiener Diethelm, Taran Florin-Andrei, Hartkopf Andreas, Meier-Stiegen Franziska, Pantel Klaus, Schneeweiss Andreas, Müller Volkmar, Alunni-Fabbroni Marianna, Trapp Elisabeth, Rack Brigitte, Huober Jens, De Gregorio Nikolaus, Scholz Christoph, Schochter Fabienne, Friedl Thomas W P, Fehm Tanja